The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index; none of the 14 sources its claims cite is checked for support yet.
Development of suspension adapted Vero cell culture process technology for production of viral vaccines
Open accessAbstract
Vero cells are considered as the most widely accepted continuous cell line by the regulatory authorities (such as WHO) for the manufacture of viral vaccines for human use. The growth of Vero cells is anchorage-dependent. Scale-up and manufacturing in adherent cultures are labor intensive and complicated. Adaptation of Vero cells to grow in suspension will simplify subcultivation and process scale-up significantly, and therefore reduce the production cost. Here we report on a successful adaptation of adherent Vero cells to grow in suspension in a serum-free and animal component-free medium (IHM03) developed in-house. The suspension adapted Vero cell cultures in IHM03 grew to similar or better maximum cell density as what was observed for the adherent Vero cells grown in commercial serum-free media and with a cell doubling time of 40–44 h. Much higher cell density (8 × 106 cells/mL) was achieved in a batch culture when three volume of the culture medium was replaced during the batch culture process. Both adherent and suspension Vero cells from various stages were tested for their authenticity using short tandem repeat analysis. Testing result indicates that all Vero cell samples had 100% concordance with the Vero DNA control sample, indicating the suspension cells maintained their genetic stability. Furthermore, suspension Vero cells at a passage number of 163 were assayed for tumorigenicity, and were not found to be tumorigenic. The viral productivity of suspension Vero cells was evaluated by using vesicular stomatitis virus (VSV) as a model. The suspension cell culture showed a better productivity of VSV than the adherent Vero cell culture. In addition, the suspension culture could be infected at higher cell densities, thus improving the volumetric virus productivity. More than one log of increase in the VSV productivity was achieved in a 3L bioreactor perfusion culture infected at a cell density of 6.8 × 106 cells/mL.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
Adherent Vero cells were successfully adapted to serum-free, animal component-free suspension culture in in-house IHM03 medium, retaining genetic stability and non-tumorigenicity. The suspension process improved VSV productivity, especially when infected at high cell density in perfusion bioreactor culture.
Key findings
- Suspension-adapted Vero cells grew in IHM03 with a doubling time of 40–44 h; adaptation succeeded only in IHM03, while commercial serum-free media led to aggregation and failed adaptation.
- Batch shake-flask cultures reached slightly above 2 × 10^6 cells/mL; replacing medium three times during batch culture increased viable cell density to 8 × 10^6 cells/mL.
- STR analysis showed 100% concordance with the Vero DNA control for adherent and suspension cells at various passages, and suspension Vero cells at passage 163 were not tumorigenic in nude mice.
- VSV productivity was higher in suspension than adherent Vero cultures; increasing infection density from 0.87 × 10^6 to 2.5 × 10^6 cells/mL raised volumetric productivity from 2.3 × 10^9 to 8.9 × 10^9 TCID50%/mL (3.8-fold), and a 3 L perfusion culture infected at 6.8 × 10^6 cells/mL achieved more than one log higher VSV productivity than 1 × 10^6 cells/mL controls.
Methods
- Adherent Vero cells (ATCC CCL-81) were adapted to suspension in serum-free IHM03 by serial passaging in shake flasks; growth was evaluated in batch, fed-batch, and medium-replacement cultures, then scaled to a controlled 3.5 L bioreactor in batch and perfusion modes.
- Authentication used short tandem repeat (STR) analysis; tumorigenicity was tested by subcutaneous injection of 10^7 suspension Vero cells at passage 163 into nude mice, with positive and negative controls.
- Viral productivity was assessed using recombinant VSV-GFP at MOI 0.1; supernatant titers were measured by TCID50%/mL on HEK293A cells using the Spearman-Karber method.
Limitations
- The paper states that further increasing infection density to 5.0 × 10^6 cells/mL did not improve VSV production, indicating potential nutrient limitation, and that the process needs optimization to avoid nutrient and other limitations.
- The paper notes the suspension-adapted cells had a longer doubling time (40–44 h) than actively growing adherent Vero cultures (~24 h), likely due partly to serum removal and shear stress.
- Evident from the text: viral productivity was evaluated only with VSV-GFP as a model, and tumorigenicity was tested at a single passage number (163), so broader vaccine virus and long-term safety conclusions are not established here.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 14 cited sources checked · 0 supported · 0 flagged
- Findingown data
Suspension adapted Vero cell cultures in IHM03 had a cell doubling time of 40-44 h.
“The suspension adapted Vero cell cultures in IHM03 grew to similar or better maximum cell density as what was observed for the adherent Vero cells grown in commercial serum-free media and with a cell doubling time of 40-44 h.”
- Also stated in: § 3.1. Adaptation of adherent Vero cells to grow in suspension in serumfree media · plain
“The Vero cells started to grow in suspension only in serum-free IHM03 medium after 5-8 weeks of adaptation process to reach a doubling time in a range between 40 and 44 h.”
Quote in the paperSubstantial claim - Also stated in: § 3.1. Adaptation of adherent Vero cells to grow in suspension in serumfree media · plain
- Findingown data
All Vero cell samples tested, including adherent and suspension adapted cells at various passages, had 100% concordance with the Vero DNA control sample in STR analysis.
“Testing result indicates that all Vero cell samples had 100% concordance with the Vero DNA control sample, indicating the suspension cells maintained their genetic stability.”
- Also stated in: § 3.3. Genetic stability of adherent and suspension adapted Vero cells over the culture passaging and maintenance process · hedged
“Electropherogram results of all samples showed 100% concordance with the Vero DNA control sample, indicating that the adherent and suspension adapted Vero cells retained their genetic stability after passaging and/or adapting to grow in suspension in serumfree IHM03 medium for many passages.”
Quote in the paperSubstantial claim - Also stated in: § 3.3. Genetic stability of adherent and suspension adapted Vero cells over the culture passaging and maintenance process · hedged
- Findingown data
Suspension adapted Vero cell cultures in IHM03 grew to similar or better maximum cell density as adherent Vero cells grown in commercial serum-free media.
“The suspension adapted Vero cell cultures in IHM03 grew to similar or better maximum cell density as what was observed for the adherent Vero cells grown in commercial serum-free media”
Quote in the paperSubstantial claim - Findingown data
Much higher cell density (8 × 10^6 cells/mL) was achieved in a batch culture when three volumes of culture medium were replaced during the batch culture process.
“Much higher cell density (8 Â 10 6 cells/mL) was achieved in a batch culture when three volume of the culture medium was replaced during the batch culture process.”
- Also stated in: § 3.2. Growth of suspension adapted Vero cell in batch cultures · plain
“The data in Fig. 2 showed the viable cell density in shake flask cultures reached 8 Â 10 6 cells/mL after 3 complete medium replacements during the batch culture process.”
Quote in the paperSubstantial claim - Also stated in: § 3.2. Growth of suspension adapted Vero cell in batch cultures · plain
- Findingown data
Suspension adapted Vero cells at passage number 163 were not found to be tumorigenic under the conditions of the study.
“Furthermore, suspension Vero cells at a passage number of 163 were assayed for tumorigenicity, and were not found to be tumorigenic.”
- Also stated in: § 3.4. Tumorigenicity of suspension adapted Vero cells · plain
“In conclusion, under the conditions of this study, the test article, suspension adapted Vero cell at a passage number of 163, was not found to be tumorigenic.”
Quote in the paperSubstantial claim - Also stated in: § 3.4. Tumorigenicity of suspension adapted Vero cells · plain
- Findingown data
Vero cells started to grow in suspension only in serum-free IHM03 medium after 5-8 weeks of adaptation process.
“The Vero cells started to grow in suspension only in serum-free IHM03 medium after 5-8 weeks of adaptation process to reach a doubling time in a range between 40 and 44 h.”
Quote in the paperSubstantial claim - Findingown data
More than one log of increase in VSV productivity was achieved in a 3L bioreactor perfusion culture infected at a cell density of 6.8 × 10^6 cells/mL.
“More than one log of increase in the VSV productivity was achieved in a 3L bioreactor perfusion culture infected at a cell density of 6.8 Â 10 6 cells/mL.”
Quote in the paperSubstantial claim - Findingown data
Adherent Vero cells were successfully adapted to grow in suspension in serum-free and animal component-free medium IHM03 developed in-house.
“Here we report on a successful adaptation of adherent Vero cells to grow in suspension in a serum-free and animal component-free medium (IHM03) developed in-house.”
Quote in the paperSubstantial claim - Findingown data
Suspension cell culture showed better productivity of VSV than adherent Vero cell culture.
“The suspension cell culture showed a better productivity of VSV than the adherent Vero cell culture.”
- Also stated in: § 3.5. Production of vesicular stomatitis virus (VSV) in adherent and suspension adapted Vero cell flask cultures · plain
“The data in Fig. 4 showed that the volumetric virus productivity of the suspension adapted Vero cell was higher than the titer achieved by the adherent Vero cell in T-flask.”
Quote in the paperSubstantial claim- Rests on an assumption: VSV is a representative model for viral productivity of other vaccine viruses.
- Also stated in: § 3.5. Production of vesicular stomatitis virus (VSV) in adherent and suspension adapted Vero cell flask cultures · plain
- Findingown data
The culture media used to grow cells in the adherent culture stage did not affect the time required to adapt adherent cells to grow in suspension.
“Experimental data indicated that the culture media (starting media) used to grow the cells in adherent culture stage did not affect time required to adapt the adherent cells to grow in suspension.”
Quote in the paperNot a substantial claim - Findingown data
Concentrations of lactate (about 20 mM/L) and ammonia (4-5 mM/L) were at normal ranges observed in other types of cell cultures.
“While the concentration of lactate (about 20 mM/L) and ammonia (4-5 mM/L), the two common inhibitory metabolites, were at normal ranges observed in other types of cell cultures.”
Quote in the paperSubstantial claim - Findingown data
Mixing IHM03 with other high performance commercial media such as HEK GM did not improve maximum cell density or cell doubling times.
“In addition, mixing IHM03 with other high performance commercial media such as HEK GM (Xell, Bielefeld, Germany) did not either improve the maximum cell density in the batch culture or cell doubling times.”
Quote in the paperNot a substantial claim - Findingown data
VSV productivity achieved in the 3L bioreactor culture was similar to the titer obtained in small shake flask cultures infected at 1 × 10^6 cells/mL.
“Fig. 6 showed that the VSV productivity achieved in the 3L bioreactor culture was similar to the titer obtained in the small shake flask cultures infected at 1 Â 10 6 cells/mL (Fig. 4)”
Quote in the paperSubstantial claim - Findingown data
Volumetric productivity improved from 2.3 × 10^9 TCID50%/mL to 8.9 × 10^9 TCID50%/mL, or 3.8 folds, when cell density at infection increased from 0.87 × 10^6 cells/mL to 2.5 × 10^6 cells/mL.
“The data in Fig. 5 showed the volumetric productivity improved from 2.3 Â 10 9 TCID 50% /mL to 8.9 Â 10 9 TCID 50% /mL, or 3.8 folds of increase, when the cell density at infection increased from 0.87 Â 10 6 cells/mL to 2.5 Â 10 6 cells/mL.”
Quote in the paperSubstantial claim - Findingreasoning
Volumetric virus productivity declined in adherent Vero culture when cell density at infection increased to 1.0 × 10^6 cells/mL from 0.30 × 10^6 cells/mL.
“while the volumetric virus productivity declined in the adherent Vero culture when the cell density at infection increased to 1.0 Â 10 6 cells/mL from 0.30 Â 10 6 cells/mL in the adherent cultures.”
Quote in the paperSubstantial claim - Findingown data
All positive control mice injected with 18C1-10T cells developed tumors at the injection site.
“All of the positive control mice (Group 2) developed tumors at the injection site as expected, although tumors were not found in other sites examined.”
Quote in the paperNot a substantial claim - Findingown data
Formation of cell aggregates was mainly due to attachment of cells to the surface of shake flask and formation of a cell ring.
“Later work showed that the formation of cell aggregates was mainly due to the attachment of cells to the surface of shake flask and formation of a cell ring.”
Quote in the paperNot a substantial claim - Findingcitation
The doubling time of 40-44 h of suspension adapted Vero cells in IHM03 was longer than the about 24 h reported in serum-containing and actively growing adherent culture.
“The doubling time (40-44 h) of suspension adapted Vero cells in IHM03 medium was longer than the about 24 h reported in serum-containing and actively growing adherent culture [15].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [15]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Findingown data
Suspension adapted Vero cells grew to a density slightly higher than 2 × 10^6 cells/mL in shake flask cultures.
“The suspension adapted Vero cell grew to a density slightly higher than 2x10 6 cells/mL in shake flask cultures (Fig. 2).”
Quote in the paperSubstantial claim - Findingown data
Analysis of residual nutrient components in spent media revealed substantial amounts of glucose (almost 20 mM/L) and amino acids at the end of culture.
“Analysis of residual nutrient components in the spent media taken from the batch culture process revealed that there were still substantial amounts of glucose (almost 20 mM/L) and amino acids in the spent media at the end of culture.”
Quote in the paperSubstantial claim - Findingown data
The maximum cell density in batch cultures was not significantly improved by feeding with Cell Boost 5 or HEK TF.
“The maximum cell density in the batch cultures was not significantly improved by feeding the batch cultures with Cell Boost 5 (Hyclone, Logan, UT) or HEK TF (Xell, Bielefeld, Germany) (data not shown).”
Quote in the paperNot a substantial claim - Findingown data
Virus productivity in the bioreactor was slightly better than in the infected control shake flask cultures with cells either from the bioreactor or from the shake flask with medium replacement.
“The virus productivity in the bioreactor (Bioreactor) was slightly better than the infected control shake flask cultures (BioR-CTL-6.8E6and SF-CTL-6E6) with the cells either from the bioreactor or from the shake flask with medium replacement”
Quote in the paperSubstantial claim - Findingown data
Further increase in cell density to 5.0 × 10^6 cells/mL at infection resulted in no further noticeable increase in VSV production.
“However, further increase in the cell density to 5.0 Â 10 6 cells/mL at infection resulted in no further noticeable increase in the VSV production, indicating a potential limitation in nutrient availability.”
Quote in the paperSubstantial claim - Findingreasoning
Far fewer cell aggregates were observed in bioreactor culture due to the reduced ratio of bioreactor wall surface to the culture volume.
“Far fewer cell aggregates were observed in bioreactor culture due to the reduced ratio of bioreactor wall surface to the culture volume.”
Quote in the paperNot a substantial claim - Findingown data
VSV production in the bioreactor and control shake flask cultures all peaked at 22 h post infection.
“Data in Fig. 8 showed that the VSV production in the bioreactor and control shake flask cultures all peaked at 22 h of post infection.”
Quote in the paperNot a substantial claim - Findingown data
VSV production increased with increasing cell density in suspension shake flask cultures.
“In addition, the VSV production increased with the increasing cell density in the suspension shake flask cultures”
Quote in the paperSubstantial claim - Findingown data
Production kinetics of VSV in the 3L bioreactor culture was faster than in the shake flask control culture.
“The data in Fig. 6 also revealed that the production kinetic of VSV in the 3L bioreactor culture was faster than in the shake flask control culture.”
Quote in the paperNot a substantial claim - Interpretationown data
Suspension adapted Vero cells maintained their genetic stability after passaging and/or adapting to grow in suspension in serum-free IHM03.
“Testing result indicates that all Vero cell samples had 100% concordance with the Vero DNA control sample, indicating the suspension cells maintained their genetic stability.”
- Also stated in: § 3.3. Genetic stability of adherent and suspension adapted Vero cells over the culture passaging and maintenance process · hedged
“Electropherogram results of all samples showed 100% concordance with the Vero DNA control sample, indicating that the adherent and suspension adapted Vero cells retained their genetic stability after passaging and/or adapting to grow in suspension in serumfree IHM03 medium for many passages.”
Quote in the paperSubstantial claim - Also stated in: § 3.3. Genetic stability of adherent and suspension adapted Vero cells over the culture passaging and maintenance process · hedged
- Interpretationown data
The bioreactor provided a possible favorable condition for virus production.
“indicating a possible favorable condition in the bioreactor for the virus production.”
Quote in the paperNot a substantial claim - Interpretationown data
It is possible to increase volumetric productivity of VSV through infection at higher cell density.
“These results indicated that it is possible to increase the volumetric productivity of VSV through infection at higher cell density.”
Quote in the paperSubstantial claim - Interpretationown data
Availability of nutrients might not be a limiting factor when the culture was infected at a low cell density such as 1 × 10^6 cells/mL.
“indicating the availability of nutrients might not be a limiting factor when the culture was infected at a low cell density such as 1 Â 10 6 cells/mL”
Quote in the paperSubstantial claim - Premisecitation
A higher cell density was achieved by Thomassen et al. when their culture was operated under a recirculation mode with cells retained in the bioreactor and 5 culture volumes of fresh medium per day circulated.
“Similarly, a higher cell density was achieved by Thomassen et al. [21], when their culture was operated under a recirculation mode, where cells were retained in the bioreactor while 5 culture volumes of fresh medium per day was circulated.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [21]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Thomassen et al. found that growth of Vero cells in stirred culture was not inhibited by lactate and ammonia at the above concentration ranges.
“Thomassen et al. [21] also found the growth of Vero cells in stirred culture was not inhibited by the lactate and ammonia at the above concentration ranges.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [21]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationown data
Perfusion was an effective means to increase maximum cell density of the culture.
“These data showed that the perfusion was an effective mean to increase maximum cell density of the culture.”
Quote in the paperSubstantial claim - Interpretationown data
Perfusion culture combined with infection at high cell density was a feasible approach to increase volumetric virus production.
“This clearly demonstrates that the perfusion culture combined with infection at high cell density was a feasible approach to increase the volumetric virus production.”
Quote in the paperSubstantial claim - Study design and conductown data
Cell viability was always higher than 98% during both batch culture processes with and without medium replacement.
“The cell viability was always higher than 98% during the both culture processes.”
Quote in the paperSubstantial claim - Premisecitation
When Vero cells were cultured in serum-free media, especially in stirred cultures, the doubling time was usually longer than 24 h.
“Therefore, it appears that, when the Vero cells were cultured in serum-free media especially in stirred cultures, the doubling time of Vero cells was usually longer than 24 h [9,3,4].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [9]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationcitation
Shear stress in suspension culture, especially without microcarrier supports, might also reduce the cell growth rate.
“Also shear stress in the suspension culture, especially in the culture without supports of microcarrier, might also reduce the cell growth rate.”
Quote in the paperNot a substantial claim - Interpretationown data
The lack of further increase in VSV production at 5.0 × 10^6 cells/mL indicated a potential limitation in nutrient availability.
“However, further increase in the cell density to 5.0 Â 10 6 cells/mL at infection resulted in no further noticeable increase in the VSV production, indicating a potential limitation in nutrient availability.”
Quote in the paperSubstantial claim - Interpretationcitation
The increased cell doubling time of suspension adapted Vero cells in serum-free cultures was more likely and partially due to the removal of serum.
“The increased cell doubling time of suspension adapted Vero cells in serum-free cultures was more likely and partially due to the removal of serum, as the removal of serum usually increased the cell doubling time, such as from 31 to 43 h [17,19]”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [17]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [19]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationcitation
Accumulation of unknown metabolites in the cellular microenvironment was probably responsible for the density-dependent inhibition of cell growth observed under the optimized environmental condition.
“Accumulation of unknown metabolites in the cellular microenvironment was probably responsible for the densitydependent inhibition of cell growth observed under the optimized environmental condition [15].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [15]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- It may state two separate claims as one. 12
- The quote only partly states this claim. 1
- Probably not a substantial claim. 3
It may state two separate claims as one.
Findingown dataSuspension culture could be infected at higher cell densities, improving volumetric virus productivity.
“In addition, the suspension culture could be infected at higher cell densities, thus improving the volumetric virus productivity.”
Quote in the paperSubstantial claimIt may state two separate claims as one.
Findingown dataCell density increased by 2.2-2.5 × 10^6 cells/mL after perfusing each bioreactor volume of medium, roughly equivalent to the maximum cell density achieved in batch culture.
“The cell density increased by 2.2-2.5 Â 10 6 cells/mL after perfusing each bioreactor volume of medium, which was roughly equivalent to the maximum cell density achieved in the batch culture.”
Quote in the paperSubstantial claimThe quote only partly states this claim.
Findingown dataNone of the mice receiving suspension adapted Vero cells at passage 163 or negative control had evidence of neoplastic cellular proliferation at the injection site or in other organs or tissues examined.
“None of the mice receiving the test article (Group 1), or serum free cell culture media only (Group 3) had evidence of neoplastic cellular proliferation, i.e. tumors, at the injection site or in other organs or tissues examined.”
Quote in the paperSubstantial claimIt may state two separate claims as one.
Findingown dataIn commercial serum-free medium cultures, Vero cells aggregated and adaptation was not successful.
“While in the commercial serum-free medium cultures, the Vero cells aggregated and the adaptation was not successful.”
Quote in the paperSubstantial claimIt may state two separate claims as one.
Findingown dataSuspension Vero cells showed similar growth rate in 3L bioreactor as in small shake flask cultures, but with much less cell aggregates.
“The suspension Vero cell showed a similar growth rate (data not shown) as those achieved in the small shake flask cultures, but with much less cell aggregates.”
Quote in the paperSubstantial claimIt may state two separate claims as one.
Findingown dataVolumetric productivity of VSV peaked at 28 h post infection in the 3L bioreactor culture, while the highest titer of VSV appeared in the shake flask culture after 45 h post infection.
“The volumetric productivity of VSV peaked at 28 h post infection in the 3L bioreactor culture, while the highest titer of VSV appeared in the shake flask culture after 45 h post infection.”
Quote in the paperNot a substantial claimIt may state two separate claims as one.
Findingown dataCell density reached 4.2 × 10^6 cells/mL after 2 days of perfusion at 0.5 VVD, and further increased to 6.8 × 10^6 cells/mL when the culture was operated at 1 VVD for one additional day before virus infection.
“The cell density reached 4.2 Â 10 6 cells/mL after 2 days of perfusion at a rate of 0.5 VVD, and further increased to 6.8 Â 10 6 cells/mL when the culture was operated at a perfusion rate of 1 VVD for one additional day before the virus infection.”
Quote in the paperSubstantial claimProbably not a substantial claim. The paper’s conclusions may not depend on it.
PremisecitationVero cells are considered the most widely accepted continuous cell line by regulatory authorities such as WHO for the manufacture of viral vaccines for human use.
“Vero cells are considered as the most widely accepted continuous cell line by the regulatory authorities (such as WHO) for the manufacture of viral vaccines for human use.”
- Also stated in: § 1. Introduction · plain
“Vero cells are considered as the most widely accepted continuous cell line by the regulatory authorities (such as WHO) for the manufacture of viral vaccines for human use [10].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [10]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Also stated in: § 1. Introduction · plain
It may state two separate claims as one.
InterpretationreasoningAdaptation of Vero cells to grow in suspension will simplify subcultivation and process scale-up significantly, and therefore reduce production cost.
“Adaptation of Vero cells to grow in suspension will simplify subcultivation and process scale-up significantly, and therefore reduce the production cost.”
- Also stated in: § 1. Introduction · plain
“Adaptation of Vero cells to grow in suspension will simplify handling of cultures such as inoculation, cell passaging and process scale-up significantly, and therefore, reduce the production cost.”
Quote in the paperSubstantial claim- Rests on an assumption: Vero cells are anchorage-dependent and can only proliferate when provided with a suitable surface.
- Also stated in: § 1. Introduction · plain
It may state two separate claims as one.
PremisecitationScale-up and manufacturing in adherent cultures are labor intensive and complicated.
“Scale-up and manufacturing in adherent cultures are labor intensive and complicated.”
- Also stated in: § 1. Introduction · plain
“Scale-up of cell mass for large-scale adherent cell-based manufacturing is of particular concern or challenging as attachmentdependent culture processing generally requires more steps (the required detachment and reattachment of cells during passaging) and time than suspension [13].”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [13]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [16]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [22]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Also stated in: § 1. Introduction · plain
Probably not a substantial claim.
Study design and conductcitationSTR analysis of Vero cell samples was performed according to the method developed by Almeida et al.
“DNA samples were extracted from adherent and suspension adapted Vero cells at various passages and shipped to the National Institute of Standards and Technology (Gaithersburg, MD) for short tandem repeat (STR) analysis according to the method developed by Almeida et al. [1].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [1]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
It may state two separate claims as one.
Interpretationown dataThe adapted cells could be used for high yield productions of viruses, such as VSV, at high cell density and in suspension cultures at reduced production cost.
“These adapted cells could be used for high yield productions of viruses, such as VSV, in at high cell density and in suspension cultures at reduced production cost.”
Quote in the paperSubstantial claim- Rests on an assumption: VSV is a representative model for viral productivity of other vaccine viruses.
It may state two separate claims as one.
Study design and conductown dataCell density in the perfusion bioreactor was verified by daily cell counts, and cell viability was always higher than 98%.
“The cell density was verified by daily cell counts, and the cell viability was always higher than 98%.”
Quote in the paperNot a substantial claimIt may state two separate claims as one.
Interpretationown dataCell growth in the batch culture might not be limited by availability of nutrients or inhibited by the common metabolites lactate and ammonia.
“These data indicate that the cell growth in the batch culture might not be limited by the availability of nutrients or inhibited by the common metabolites, lactate and ammonia.”
Quote in the paperSubstantial claimProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
InterpretationreasoningThe slightly declined virus productivity in adherent culture could be due to increased confluence percentage of monolayer or availability of nutrients in the T-flask culture.
“The slightly declined virus productivity could be due to increased confluence percentage of monolayer or availability of nutrients in the T-flask culture.”
Quote in the paperNot a substantial claim
The paper relies on this without support.
Vero cells are anchorage-dependent and can only proliferate when provided with a suitable surface.
“The growth of Vero cells is anchorage-dependent.”
“The growth of Vero cells is anchorage-dependent and Vero cells can only proliferate when provided with a suitable surface.”
The paper relies on this without support.
VSV is a representative model for viral productivity of other vaccine viruses.
“Recombinant vesicular stomatitis virus expressing the green fluorescent protein (VSV-GFP) [20], a generous gift of Dr. John Bell, Ottawa Hospital Research Institute, was selected as a model virus to evaluate the virus productivity of adherent and suspension adapted Vero cells.”
Citations
Cites
Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche
Kärber, G. (1931) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf01863914 · Cited by 3,074
Stojdl, D., Lichty, B., TENOEVER, B., Paterson, J., Power, A., Knowles, S., Marius, R., Reynard, J., Poliquin, L., Atkins, H., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00241-1 · Cited by 894 · cited 1×
“Recombinant vesicular stomatitis virus expressing the green fluorescent protein (VSV-GFP) [20], a generous gift of Dr. John Bell, Ottawa Hospital Research Institute, was selected as a model virus to evaluate the virus productivity of adherent and suspension adapted Vero cells.”
Designing cell lines for viral vaccine production: Where do we stand?
Genzel, Y. (2015) · Biotechnology Journal · doi:10.1002/biot.201400388 · Cited by 119
Rourou, S., van der Ark, A., van der Velden, T., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.086 · Cited by 103 · cited 3×
“This cell density was higher than or similar to what reported in microcarrier cultures [17,3,21].”
Barrett, P. N., Berezuk, G. P., Fritsch, S., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62228-3 · Cited by 100
Large-scale microcarrier culture of HEK293T cells and Vero cells in single-use bioreactors
Yang, J., Guertin, P., Jia, G., et al. (2019) · AMB Express · doi:10.1186/s13568-019-0794-5 · Cited by 73
Liu, C., Lian, W., Butler, M., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.083 · Cited by 71 · cited 1×
“Vero cells are susceptible to a broad range of viruses and have been widely and commercially used, after propagation on microcarriers, for the production of rabies, polio, enterovirus 71, influenza and other vaccines [11,17,2].”
Nahapetian, A. T., Thomas, J. N., & Thilly, W. G. (1986) · Journal of Cell Science · doi:10.1242/jcs.81.1.65 · Cited by 69
Rourou, S., Ben Zakkour, M., & Kallel, H. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.05.092 · Cited by 53
Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations
Knežević, I., Stacey, G., Petricciani, J. C., et al. (2009) · Biologicals · doi:10.1016/j.biologicals.2009.08.019 · Cited by 46
Authentication of African green monkey cell lines using human short tandem repeat markers
Almeida, J. L., Hill, C. R., & Cole, K. D. (2011) · BMC Biotechnology · doi:10.1186/1472-6750-11-102 · Cited by 43
Improved poliovirus d-antigen yields by application of different Vero cell cultivation methods
Thomassen, Y. E., Rubingh, O., Wijffels, R. H., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.02.022 · Cited by 42 · cited 3×
“Thomassen et al. [21] also found the growth of Vero cells in stirred culture was not inhibited by the lactate and ammonia at the above concentration ranges.”
Peschel, B., Frentzel, S., Laske, T., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.09.051 · Cited by 41
Production of yellow fever virus in microcarrier-based Vero cell cultures
Souza, M. C. O., Freire, M. D. S., Schulze, É. A., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.06.023 · Cited by 39 · cited 1×
“…more likely and partially due to the removal of serum, as the removal of serum usually increased the cell doubling time, such as from 31 to 43 h [17,19]; Also shear stress in the suspension culture, especially in the culture without supports of microcarrier, might also reduce the cell growth rate.”
Chen, A., Poh, S. L., Dietzsch, C., et al. (2011) · BMC Biotechnology · doi:10.1186/1472-6750-11-81 · Cited by 32
Elahi, S. M., Shen, C. F., & Gilbert, R. (2018) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2018.11.023 · Cited by 27
Self-citationVirus Production in Vero Cells Using a Serum-free Medium
Kolell, K., Padilla-Zamudio, J. A., Schuchhardt, B., et al. (2007) · Springer eBooks · doi:10.1007/978-1-4020-5476-1_102 · Cited by 4 · cited 1×
“Therefore, it appears that, when the Vero cells were cultured in serum-free media especially in stirred cultures, the doubling time of Vero cells was usually longer than 24 h [9,3,4].”
Media formulation to support the growth of Vero cells in suspension
Logan, M., & Aucoin, M. G. (2018) · Cited by 4
Rourou, S., Zakour, M. B., & Kallel, H. (2018) · Cited by 1
Flagged first, then by citations
Research works printed but not linked: 2
- Madeline, 2015, Culturing a duck es-derived cell line in single-use bioreactors: a rapid, efficient, and cost-effective vaccine manufacturing system based on suspension culture., Bioprocess Int, 13, 26
- Morrow KJ, Sha M. Vero Cell-based Vaccine Production: Rabies and Influenza Cell lines, Media and Bioreactor Options. Review Article. 2013. <https://online-shop.eppendorf.us/US-en/eshopdownload/downloadbykey/93796_186> [accessed 29.11.2018].
Cited by
Sorted by citations
Vero cell upstream bioprocess development for the production of viral vectors and vaccines
Kießlich, S., & Kamen, A. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107608 · Cited by 164
Self-citationA Beginner’s Guide to Cell Culture: Practical Advice for Preventing Needless Problems
Weiskirchen, S., Schröder, S. K., Buhl, E. M., & Weiskirchen, R. (2023) · Cells · doi:10.3390/cells12050682 · Cited by 148
“Nevertheless, also some adherent cell lines can be adapted to grow in suspension, which allows for more manageable cell culturing at larger scales with higher yields in special applications [11,12].”
BackgroundFang, Z., Lyu, J., Li, J., Li, C., Zhang, Y., Guo, Y., Wang, Y., Zhang, Y., & Chen, K. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.921755 · Cited by 66
“The combination of fine process control in biotechnology and the screening and domestication of highexpression cell lines can improve production efficiency and product quality, and reduce cost (Pau et al., 2001; Pan et al., 2019; Shen et al., 2019).”
BackgroundJang, M., Pete, E. S., & Bruheim, P. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.964397 · Cited by 56
Overview on Chikungunya Virus Infection: From Epidemiology to State-of-the-Art Experimental Models
Constant, L. E. C., Rajsfus, B. F., Carneiro, P. H., Sisnande, T., Mohana‐Borges, R., & Allonso, D. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.744164 · Cited by 59
Matanguihan, C., & Wu, P. Y. K. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102828 · Cited by 46
Kießlich, S., Losa, J., Gélinas, J., & Kamen, A. (2020) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2020.01.015 · Cited by 41
Self-citationProduction of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells
Gélinas, J., Azizi, H., Kießlich, S., Lanthier, S., Perdersen, J., Chahal, P. S., Ansorge, S., Kobinger, G., Gilbert, R., & Kamen, A. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.09.044 · Cited by 38
Self-citationBioreactor production of rVSV‐based vectors in Vero cell suspension cultures
Kießlich, S., Kim, G. N., Shen, C. F., et al. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27785 · Cited by 34
“Lately, studies have reported the successful adaptation using proprietary media (Rourou et al., 2019; Shen et al., 2019).”
BackgroundMethodInfluentialSelf-citationFulber, J. P. C., & Kamen, A. (2022) · Viruses · doi:10.3390/v14050975 · Cited by 35
“In 2021, our group published 1 L bioreactor productions of NDV constructs based on the LaSota strain [3] using a recently developed suspension Vero cell line [112] in commercial serum-free media.”
BackgroundMethodSelf-citationComparable respiratory activity in attached and suspended human fibroblasts
Zdrazilova, L., Hansikova, H., & Gnaiger, E. (2022) · PLOS ONE · doi:10.1371/journal.pone.0264496 · Cited by 28
“These include metabolic profiling [1], substrate diffusion [2], cell morphology and rheology [3], macrophage adherence [2], suspension culture as mimetic of circulating tumor cells [4], metastatic potential [4], therapeutic cell reimplantation, and cell culture biotechnology and pharmacology [5].”
MethodFulber, J. P. C., Farnós, O., Kießlich, S., et al. (2021) · Vaccines · doi:10.3390/vaccines9111335 · Cited by 27
“However, recent advances in adapting Vero cells to suspension have been successful [24], as these suspension Vero cells have been shown to work for virus production using stirred tank bioreactors in batch [34] and perfusion [24] modes.”
BackgroundMethodSelf-citationScalable Processes for Culturing Meat Using Edible Scaffolds
Kawecki, N. S., Chen, K. K., Smith, C. S., Xie, Q., Cohen, J. M., & Rowat, A. C. (2024) · Annual Review of Food Science and Technology · doi:10.1146/annurev-food-072023-034451 · Cited by 32
Development and scale-up of rVSV-SARS-CoV-2 vaccine process using single use bioreactor
Ton, C., Stabile, V., Carey, E., et al. (2023) · Biotechnology Reports · doi:10.1016/j.btre.2023.e00782 · Cited by 25
Suspended cell lines for inactivated virus vaccine production
Zhang, J., Qiu, Z., Wang, S., et al. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2214219 · Cited by 25
“Vero cells are adherent cells that can only proliferate when a suitable surface is provided [65].”
BackgroundMethodZinnecker, T., Reichl, U., & Genzel, Y. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2373521 · Cited by 24
“49 Moreover, doubling times exceeding 40 h and the frequent formation of aggregates remain significant issues, thereby limiting the options for efficient or intensified processes.”
BackgroundInfluentialSuspension culture of Vero cells for the production of adenovirus type 5
Lee, D.-K., Park, J., & Seo, D. (2020) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2020.9.1.48 · Cited by 24
“Another study demonstrated that suspension-adapted Vero cells produced 3-fold higher amounts of viruses than adherent Vero cells [7].”
BackgroundMore, G. K., Makola, R. T., & Prinsloo, G. (2021) · Viruses · doi:10.3390/v13020221 · Cited by 23
“They have been generally utilized in toxicology, virology and pharmacology research, as well as in the production of vaccines and diagnostic reagents [70,71].”
BackgroundSène, M., Xia, Y., & Kamen, A. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.40 · Cited by 22
Self-citationGöbel, S., Kortum, F., Chavez, K. J., Jordan, I., Sandig, V., Reichl, U., Altomonte, J., & Genzel, Y. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-12027-5 · Cited by 21
“2013), only a few publications reported the yield of VSV-based vectors from suspension cell culture (Elahi et al. 2019; Shen et al. 2019), and rVSV-NDV production in suspension cells has never been addressed before.”
Haplotype-resolved de novo assembly of the Vero cell line genome
Sène, M., Kießlich, S., Djambazian, H. H. V., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00358-9 · Cited by 21
Self-citationDevelopment of Robust Freeze-Drying Process for Long-Term Stability of rVSV-SARS-CoV-2 Vaccine
Khan, M. F. H., Youssef, M., Nesdoly, S., et al. (2024) · Viruses · doi:10.3390/v16060942 · Cited by 18
“Suspension Vero cells (originated from ATCC CCL-81) were cultured in Kamen’s lab (McGill University) and used for this study [34].”
MethodSelf-citationSilva, C. A. T., Kamen, A., & Henry, O. (2021) · The Canadian Journal of Chemical Engineering · doi:10.1002/cjce.24197 · Cited by 16
Self-citationAnimal Cell Lines as Expression Platforms in Viral Vaccine Production: A Post Covid-19 Perspective
Demirden, S. F., Gebologlu, I. K., & Öncel, S. Ş. (2024) · ACS Omega · doi:10.1021/acsomega.3c10484 · Cited by 18
Adeosun, W. B., More, G. K., Steenkamp, P. A., & Prinsloo, G. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.961859 · Cited by 14
“They have been widely used in toxicology, virology, and pharmacology studies, as well as vaccine development and diagnostic reagent production (Wu et al., 2017; Shen et al., 2019).”
MethodFeuerherd, M., Sippel, A.-K., Erber, J., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99742-7 · Cited by 14
Sène, M., Xia, Y., & Kamen, A. (2023) · International Journal of Cell Biology · doi:10.1155/2023/9364689 · Cited by 12
Self-citationShen, C. F., Burney, E., Gilbert, R., Elahi, S. M., Parato, K. A., & Loignon, M. (2023) · Biotechnology Journal · doi:10.1002/biot.202300244 · Cited by 12
“[19] When HEK293 and A549 cultures are fed with these three feeds for a production of adenovirus or lentivirus, there is no delayintheinfectionkineticorvirusproductionintheculturesinfected without medium replacement.”
BackgroundMethodInfluentialSelf-citationA microfluidic cell chip for virus isolation via rapid screening for permissive cells
Su, W., Qiu, J., Mei, Y., et al. (2022) · Virologica Sinica · doi:10.1016/j.virs.2022.04.011 · Cited by 12
“A549, Vero, RD, MDCK, and BHK-21 cell lines, which are sensitive to different viruses (including enterovirus, simplexvirus, vesiculovirus, Ebola-like viruses, and flavivirus) (Phanthanawiboon et al., 2014; Alonso and Compans, 1981; Puhl et al., 2021; Shen et al., 2019; Xiao et al., 2020; Lee and Fuller, 1993; Drews et…”
MethodWang, P., Huang, S., Hao, C., Wang, Z., Zhao, H., Liu, M., Tian, X., Ge, L., Wu, W., & Peng, C. (2021) · Vaccines · doi:10.3390/vaccines9091006 · Cited by 11
“For now, a variety of cells, including MDCK cells [26], CHO cells [27], HEK 293SF cells [2], BHK21 cells [28] and Vero cells [29], have been successfully adapted to suspended growth in serumFigure 6.”
BackgroundYang, Z., Paes, B. C. M. F., Fulber, J. P. C., Tran, M. Y., Farnós, O., & Kamen, A. (2023) · Vaccines · doi:10.3390/vaccines11040841 · Cited by 11
“The suspension Vero cell line was provided by National Research Council Canada (NRC) [17].”
BackgroundMethodInfluentialSelf-citationLuo, X., Niu, Y., Fu, X., et al. (2021) · Vaccines · doi:10.3390/vaccines9091003 · Cited by 10
Eckhardt, D., Mueller, J., Friedrich, J., et al. (2024) · Viruses · doi:10.3390/v16111740 · Cited by 10
Khan, M. F. H., Wagner, C. E., & Kamen, A. (2024) · Vaccines · doi:10.3390/vaccines12111240 · Cited by 8
Self-citationCharacterization of a suspension Vero cell line for viral vaccine production
Bourigault, L., Bresson, C., Jean, C., Chevalard, C., Kloutz, M., Soulet, D., Pelissier, F., Richard, S., Bassard, I., Sève, N., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01157-2 · Cited by 8
Construction of a peacock immortalized fibroblast cell line for avian virus production
Wang, J., Yu, X., Zhao, S., Zhang, N., Lin, Z., Wang, Z., Ma, J., Yan, Y., Sun, J., & Cheng, Y. (2022) · Poultry Science · doi:10.1016/j.psj.2022.102147 · Cited by 6
“Vesicular stomatitis virus (VSV) is often used as a model for assessing cellular viral productivity (Shen et al., 2019).”
BackgroundRollando, R., Warsito, W., Masruri, M., et al. (2021) · Pakistan Journal of Biological Sciences · doi:10.3923/pjbs.2021.172.181 · Cited by 6
Vero cells gain renal tubule markers in low-calcium and magnesium chemically defined media
Logan, M., Rinas, K., McConkey, B. J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10221-z · Cited by 6
Sène, M., Xia, Y., & Kamen, A. (2021) · Research Square · doi:10.21203/rs.3.rs-1014921/v1 · Cited by 6
Self-citationProhibitin1 facilitates viral replication by impairing the RIG-I-like receptor signaling pathway
Zou, J., Tian, S., Zhu, Y., et al. (2023) · Journal of Virology · doi:10.1128/jvi.00926-23 · Cited by 5
“To further confirm this point, type I IFN genedeficient Vero cells and MAVSdeficient MDCK cells were infected with SeV (32), and the PHB1 protein and mRNA levels were hardly changed after SeV infection in these cells (Fig.”
Kuo, H., Srinivasan, P., Lin, Y., Lu, M., Rungkittikhun, C., Zhang, Q., & Hu, W. (2025) · Biotechnology Progress · doi:10.1002/btpr.70042 · Cited by 4
“19 22 While adherent cells could be grown on microcarriers using stirred tanks, suspension cultures are far simpler for large-scale operations.”
Silva, C. A. T., Kamen, A., & Henry, O. (2024) · Biotechnology Progress · doi:10.1002/btpr.3506 · Cited by 4
Self-citationBarbosa, R. D. M., Silva, A. M., da Silva, C. F., Cardoso, J. C., Severino, P. B., Meirelles, L. M. A., da Silva-Júnior, A. A., Viseras, C., Fonseca, J., & Souto, E. B. (2022) · Technologies · doi:10.3390/technologies10050109 · Cited by 4
Expression Levels of ACE2 and TMPRSS2 in Different Cell Lines
Albayrak, M. G. B., Yanar, S., Kasap, M., et al. (2023) · Acta Medica Nicomedia · doi:10.53446/actamednicomedia.1253701 · Cited by 4
Sevda, S., & Kumar, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15378-5.00001-2 · Cited by 4
Robitaille, J., Manceur, A. P., Rodenbrock, A., & Loignon, M. (2024) · Biochemistry · doi:10.5772/intechopen.114000 · Cited by 3
Metabolic Responses and Pathway Changes of Vero Cells under High-Vitamin B Medium
Yu, S., Yan, J., Yang, Z., et al. (2022) · Vaccines · doi:10.3390/vaccines10111787 · Cited by 3
Choi, H.-Y., Choi, J.-C., Kang, Y.-L., et al. (2023) · BMC Veterinary Research · doi:10.1186/s12917-023-03659-4 · Cited by 2
“Presently, large-scale microcarrier culture is routinely used for vaccine production in bioreactors [11, 12].”
BackgroundAnimal cell culture in vaccine production
Sandhu, K., Bhadra, S., Chockalingam, S., et al. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15378-5.00007-3 · Cited by 1
Nagorska, A., Tomás, R. M. F., Tasnim, A., et al. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c00760 · Cited by 1
Lim, J. S., Kim, J. S., Cheon, Y., Park, T. S., & Hong, J. K. (2024) · Animal Bioscience · doi:10.5713/ab.24.0372 · Cited by 1
Developing an oncolytic Newcastle disease virus production process with EB66 cells
Jacobtorweihe, L., Saulnier, A., Léon, A., et al. (2026) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-026-13889-9 · Cited by 1
“However, suspension Vero cells are currently difficult to cultivate at concentrations above 6.0 × 10 6 cells/mL (Shen 2019).”
InfluentialWeber, L. G., & Wolff, M. W. (2026) · Expert Review of Vaccines · doi:10.1080/14760584.2026.2689611 · Cited by 1
Promising opportunities to improve polio vaccines
Evreinova, E. E., Khantimirova, L. M., Шевцов, В. А., Меркулов, В. А., & Бондарев, В. П. (2022) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2022-22-2-336 · Cited by 2
Epidermal Growth Factor Promotes E6 and CCL-81 Vero Cells Proliferation Under Serum-Free Condition
Delaiah, D., Aswin, A., Susilowati, H., et al. (2024) · Jurnal Medik Veteriner · doi:10.20473/jmv.vol7.iss1.2024.1-6 · Cited by 1
Vaccine Technology VII: Beyond the “decade of vaccines”
Kamen, A., Lua, L. H. L., & Mukhopadhyay, T. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.09.083 · Cited by 1
Self-citationVirus Purification Framework And Enhancement In Aqueous Two-Phase System
Joshi, P. U. (2020) · doi:10.37099/mtu.dc.etdr/1030 · Cited by 1
Bioreactor production of rVSV-vectored vaccines in Vero cell suspension culturesPreprint
Kießlich, S., Kim, G., Shen, C. F., et al. (2021) · doi:10.22541/au.161044033.35250019/v1 · Cited by 1
“Cell growth in batch bioreactor The suspension adapted Vero cells showed similar growth in IHM03 medium in 1L batch bioreactors as previously reported, reaching 1.78 x 106 cells/mL after 6 days (Shen et al., 2019).”
BackgroundMethodResultInfluentialSelf-citationDevelopment of a Vero cell platform for rVSV vector production
Kießlich, S. (2021) · doi:10.82308/51144 · Cited by 1
UJI TOKSISITAS KITOSAN SISIK IKAN HARUAN (Channa striata) TERHADAP SEL VERO
Maulana, A. F., Putri, D. K. T., & Azizah, A. (2022) · Dentin · doi:10.20527/dentin.v6i2.6390
Improved Production Strategies for Oncolytic Measles Viruses as a Therapeutic Cancer Treatment
Eckhardt, D., Bossow, S., Klee, J.-P., et al. (2023) · Springer eBooks · doi:10.1007/978-3-031-28489-2_16
Upstream Processing of Viral Therapeutics: From Host Cell Expansion to Virus Production
Hamusics, O., & Loewe, D. (2023) · Springer eBooks · doi:10.1007/978-3-031-28489-2_3
Scale-up of cell-culture bioreactors
Rajulapati, V., & Marszałek, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15378-5.00004-8
Shang, Q., Sun, J., Wang, J., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7782639/v1
Shen, C. F., Burney, E., Gilbert, R., et al. (2025) · BMC Biotechnology · doi:10.1186/s12896-025-01051-8
“These results resonate with our previous observations in suspension Vero cell fed-batch cultures [19].”
Self-citationEckhardt, D., Klee, J.-P., Sardlishvili, I., Mueller, J., Walter, L. E., Fey, S., Thorbow, J., Hofmann, T., Zimmer, A., Czermak, P., et al. (2025) · Vaccine X · doi:10.1016/j.jvacx.2025.100760
Optimization of initial culture stage of Vero and HEK293 cell lines
И.И., Т., Чиркина, Т. И., Churkin, I. A., et al. (2025) · Extreme Medicine · doi:10.47183/mes.2025-324
Çolak, G., Uzar, S., & Birbir, M. (2025) · BMC Biotechnology · doi:10.1186/s12896-025-01089-8
“Several other viruses have also been produced in Vero cells using Cytodex 1 MCs within spinner flasks or bioreactor systems [26, 27, 29, 30, 53, 54, 56].”
Sun, F., Yu, H., Zhang, T., et al. (2026) · Journal of AOAC International · doi:10.1093/jaoacint/qsag019
Peng, R., Jia, R., Huang, R., Li, M., Li, X., Zhou, M., Wang, J., Qiao, Z., & Sun, N. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1777187
“Recent adaptations using proprietary media by Rourou, Shen, and Logan improved cell survival but revealed persistent issues including prolonged doubling times and pronounced autophagy/mitophagy (Rourou et al., 2019; Shen et al., 2019; Logan et al., 2022).”
Self-citationTranscriptome‐Based Analysis of Core Hub Genes Related to Cell Adhesion in Vero Cells
Fan, Y., Wang, Y., Bi, R., Zhao, Y., Gao, W., Zhang, D., Li, Q., & Bai, J. (2026) · BioMed Research International · doi:10.1155/bmri/1265156
“To meet the global demand for vaccines, suspension culture technology of Vero cells has remained a prominent research focus [15].”
Gottipamula, S., & Krishnan, V. N. (2026) · Biotechnology and Bioengineering · doi:10.1002/bit.70324
Engineering the Vero Cell Lineage: Toward a Programmable Vaccine Manufacturing Platform
Zhang, H., Wang, Z., & Yang, Z. (2026) · Biotechnology and Bioengineering · doi:10.1002/bit.70374
Immunogenicity of a Vero cell-adapted Japanese encephalitis attenuated virus strain SA14-14-2 VC6
Liu, X., Fang, E., Xu, H., et al. (2026) · Archives of Virology · doi:10.1007/s00705-026-06698-y
“Vero cells are widely used in the production of human vaccines (e.g., polio, rabies, influenza) and have a proven safety record [29].”
Hong, R., Blanda, T. R., Bednar, M., et al. (2026) · Biotechnology Progress · doi:10.1002/btpr.88561
Metadata
- Authors
- Shen, C. F., Guilbault, C., Li, X., Elahi, S. M., Ansorge, S., Kamen, A., & Gilbert, R.
- Affiliations
- National Research Council Canada (CA)
- China National Biotechnology (China) (CN)
- Corresponding author
- Shen, Chun Fang
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 37
- Issue
- 47
- Pages
- 6996-7002
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2953696603
- Semantic Scholar
- 498ea0626d7be6b6769121e4ddc40adaa2ea2b17
- Cited by
- 75
- References
- 19
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 14 · 2023: 11 · 2022: 15 · 2021: 13 · 2020: 4 · 2019: 2
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Vaccine (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institute of Standards and Technology
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Physical Sciences › Chemical Engineering › Fluid Flow and Transfer Processes › Fluid Dynamics and Mixing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- Vero cells, cell suspension culture, viral vaccine production, serum-free medium, cell line authentication, short tandem repeat profiling, vesicular stomatitis virus, perfusion bioreactor, adherent culture, process scale-up
- MeSH terms
- Animals, Cell Count, Cell Line, Chlorocebus aethiops, Culture Media, Vero Cells, Vesicular stomatitis Indiana virus, Viral Vaccines, Virus Cultivation, Culture Media, Serum-Free, Vesiculovirus, Bioreactors, Batch Cell Culture Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review